Efficacy and safety of adjuvant low-dose apatinib combined with SOX regimen versus SOX regimen in patients with resectable locally advanced gastric cancer: a cohort study.

Front Pharmacol · 2026 · PMC13051217 · PMID 41948723

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Moreover, hypertension showed a higher tendency in apatinib + SOX group compared to SOX group (22.9% versus 10.0%, P = 0.093), but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.